Sharps Technology Inc - STSSW STOCK NEWS

Sharps Technology (NASDAQ: STSS) has signed an enhanced Asset Purchase Agreement with Nephron Pharmaceuticals to acquire InjectEZ manufacturing assets in South Carolina. The $35 million acquisition includes a five-year, $200 million syringe Sales Agreement, positioning Sharps as the first dedicated polymer prefillable syringe manufacturer in North America. Expected revenues are $35 million in the first 12 months, with potential growth to $100 million by 2028. The facility will start delivering products by Q2 2025. The deal also involves a $9 million and $4.75 million investment for production line expansions, potentially adding $65 million in annual revenue by 2027. This strategic move is fueled by FDA recalls, tariffs, and a shift from glass to polymer syringes.

Sharps Technology has signed a $200 million, 5-year syringe sales agreement with Nephron Pharmaceuticals and an asset purchase agreement (APA) to acquire InjectEZ's syringe manufacturing assets for $35 million. This acquisition, expected to close within 60 days, will establish a dedicated prefillable syringe manufacturing plant in West Columbia, SC. The facility aims to start production by Q2 2025, projecting $37 million in revenue in the first 12 months. This deal expands Sharps' manufacturing capacity in the U.S. and Europe and positions the company for growth in the copolymer prefillable syringe market.

Sharps Technology (NASDAQ: STSS) CEO Robert Hayes addresses shareholders about the impact of recent FDA actions and tariffs. The FDA raised quality concerns over Chinese syringes in November 2023, leading to recalls and warnings in early 2024. The Biden Administration increased tariffs on Chinese syringes from 0% to 50% in May 2024. Sharps Technology, with its high-quality syringe products like SecureGard and SoloGard, is poised to fill the supply gap. The company manufactures in Hungary and plans to add a US facility. Sharps has also formed partnerships with Roncadelle Operations and Owens & Minor to expand market reach and distribution. These steps are expected to drive revenue growth and market presence.

Sharps Technology, Inc. and Roncadelle Operations have signed a sales and distribution agreement to expand their market reach globally. The agreement allows Sharps to enter Europe, the Middle East, Africa, and Asia-Pacific, while Roncadelle gains access to North and Latin American markets. This collaboration aims to provide healthcare customers with a wide range of smart safety syringes and drug delivery solutions. Both companies are dedicated to innovation and excellence in reshaping global healthcare standards.

Sharps Technology, Inc. is set to introduce its Securegard smart safety syringe line to the Latin American healthcare market, with initial orders for the 1mL and 3mL syringes already in process. The collaboration with a distribution partner in Colombia aims to promote safer healthcare practices in the region, offering clinicians ultra-low waste drug delivery technology with active safety features and re-use prevention measures. The introduction of Securegard syringes can enhance healthcare quality in Latin America and beyond, with manufacturing underway for delivery within the next 90 days.

Sharps Technology, Inc. (STSS) partners with Roncadelle Operations to expand its global healthcare market presence through new 3PL partnerships, aiming to develop and distribute innovative drug delivery solutions worldwide.

Sharps Technology, Inc. (NASDAQ: STSS) and Roncadelle Operations signed a Letter of Intent to enter into a sales and marketing agreement, aiming to expand Sharps' product market into Europe, the Middle East, Africa, and the Asia-Pacific region. The agreement would allow both companies to sell and distribute each other's products, leveraging their respective areas of influence. The LOI is subject to the negotiation of definitive documentation, and there is no assurance that the parties will enter into a definitive agreement.

Sharps Technology, Inc. announces the closing of its registered direct offering and private placement, raising approximately $5.6 million. The funds will be used for working capital and general corporate purposes.

Sharps Technology, Inc. has signed an Asset Purchase Agreement to acquire the InjectEZ facility and a 10-year purchase agreement with Nephron Pharmaceuticals. The acquisition will enable Sharps to enter the prefilled syringe market and provide long-term revenue stability and growth. The company has also secured a term sheet for up to $75 million in debt financing. The InjectEZ facility is a state-of-the-art manufacturing facility with plans for expansion to double its capacity. Operations in the company's wholly owned facility in Hungary are progressing as planned.